As many as 60% of BrCA patients receiving radiation are known to develop fatigue with about 30% suffering persistent fatigue several months to years after treatment completion. The nuclear factor-kB (NF-kB) pathway has emerged as having an important role not only in cancer treatment resistance, but also in the development of fatigue. This project will explore the effectiveness of Meriva, a formulation of the natural product curcumin already shown to target NF-kB, to attenuate fatigue in women after treatment for breast cancer. For more information on this study please click here. This study is no longer recruiting.

Emory University Behavioral Immunology Program

Emory University Clinic B
1365 Clifton Road NE
Suite B5101
Atlanta, GA 30322